Study on the Effect of Different anti-VEGF drugs on Fibrovascular Membrane of Proliferative Diabetic Retinopathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300067476

Enrollment

Unknown

Registered

2023-01-09

Start date

2020-10-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy

Interventions

Ranibizumab group:Ranibizumab

Conbercept group:Conbercept

Aflibercept group:Aflibercept

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years;2.Diagnosed as proliferative diabetic retinopathy, IV to VI diabetic retinopathy (DM); 3. Patients with surgical indications;3.PDR eyes with the FVM requiring surgical intervention;4.3 months before the injection of antiangiogenic factor drugs or dexamethasone patients;5.At least partial corneal transparency (or central corneal transparency), Can FVM be detected clearly by OCTA.

Exclusion criteria

Exclusion criteria: (1) Eyes with other neovascular retinopathy such as wet age-related macular degeneration (wAMD) and retinal vein obstruction (RVO) (2) Eyes with refractive interstitium opacity affecting the quality of OCTA imaging (3) Eyes with any ocular surgery and laser photocoagulation histories in 3 months, especially a history of PPV or intravitreal injection of anti-VEGF drugs (4) Patients with severe cardiopulmonary impairment, liver diseases, renal dysfunction, and advanced stage of cancer.

Design outcomes

Primary

Measure	Time frame
OCTA(Optical Coherence Tomography Angiography);	—

Countries

China

Contacts

Public ContactYan Shao, Xiaorong Li

Tianjin Medical University Eye Hospital

xiaorli@163.com17622651170,18622818042

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026